Two Deaths Linked to Unapproved Retatrutide Use

The FDA received reports of two patient fatalities involving the experimental drug retatrutide, which is not approved for sale.

Updated on Oct. 13, 2026 in Diabetes

Bold flat-color editorial illustration featuring a minimalist architectural facade, evoking the gravity of unregulated pharmaceutical risks. — The FDA confirmed two patient fatalities linked to unauthorized, unapproved versions of the experimental weight-loss drug retatrutide obtained from online vendors. AI Illustration. Upload story photo >

Two patients died in the United States after using unauthorized versions of the experimental drug retatrutide. The FDA received reports of these fatalities following incidents in July and September 2026.

Why it matters

The deaths underscore significant risks associated with purchasing unapproved medications from unreliable online sources. Eli Lilly, the developer of retatrutide, has initiated legal action against companies selling unauthorized versions of the experimental drug.

America's Poison Centers documented 862 exposures to retatrutide during the three months ending in September 2026. This figure marks a significant rise from the 460 exposures reported in the prior quarter.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by regulating the safety and efficacy of drugs.

Eli Lilly

Eli Lilly is a pharmaceutical corporation that developed retatrutide as an experimental drug currently awaiting formal approval.

America's Poison Centers

This organization maintains a network of centers that provide free, confidential medical advice to the public regarding potential toxic exposures.

The details

Patients obtained the non-FDA-approved drug through online peptide vendors or other unreliable sources. Reported complications included cardiac arrest, dehydration, and malnutrition.

A 41-year-old woman died in July 2026 following cardiac arrest.
A 49-year-old patient died in September 2026 due to dehydration and cardiac arrest.
America's Poison Centers recorded 862 exposures to the drug in the third quarter of 2026.

Health Landscape

The distribution of unapproved drugs constitutes a clear violation of the Federal Food, Drug, and Cosmetic Act. These incidents highlight the ongoing regulatory challenge of protecting consumers from illegal, off-market pharmaceutical products.

Patients are strongly cautioned that retatrutide is not FDA-approved and remains an experimental drug. Individuals seeking weight loss or diabetes treatment should only obtain medications prescribed by a licensed healthcare provider through legitimate pharmacies.

The takeaway

Consumers must avoid purchasing injectable drugs from online retailers that do not require a verified medical prescription. Always consult with a doctor to discuss safe, FDA-approved therapeutic options for obesity or diabetes management.